Loading...
Please wait, while we are loading the content...
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
| Content Provider | Europe PMC |
|---|---|
| Author | Park, Sehhoon Ku, Bo Mi Jung, Hyun Ae Sun, Jong-Mu Ahn, Jin Seok Lee, Se-Hoon Park, Keunchil Ahn, Myung-Ju |
| Copyright Year | 2020 |
| Abstract | The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines. |
| ISSN | 15982998 |
| Journal | Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| Volume Number | 52 |
| PubMed Central reference number | PMC7577810 |
| Issue Number | 4 |
| PubMed reference number | 32599977 |
| e-ISSN | 20059256 |
| DOI | 10.4143/crt.2020.278 |
| Language | English |
| Publisher | Korean Cancer Association |
| Publisher Date | 2020-06-22 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2020 by the Korean Cancer Association |
| Subject Keyword | Non-small cell lung cancer Lazertinib Third-generation EGFR tyrosine kinase inhibitor ErbB receptors |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Oncology |